The impact of current therapeutic options on the health-related quality of life of patients with relapse/refractory multiple myeloma: a systematic review of clinical studies

Ojo, A. O.; Araoye, Mojisola O.; Ali, Ahmed Said; Sarma, Ravi

doi:10.1007/s11764-023-01332-1

Cited by 4 publications

(3 citation statements)

References 96 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…These advances are reflected in the dramatic improvements in the 5-year survival rates for the disease, which had risen gradually from 25% in the 1975-77 period to 32% for 1995-97 but climbed sharply to 58% during 2012-2018 as the impact of these newer modalities began to come into play [2]. The benefits of these therapeutic advances are further evidenced by such measures as accumulated survival and response data and studies demonstrating an improved quality of life [255,256]. The characterization of MM itself has changed over the years, shifting from the traditional CRAB model toward a paradigm that includes molecular and immunologically based factors that may be evidence of the disease before signs and symptoms emerge.…”

Section: Discussionmentioning

confidence: 99%

Immunotherapy of Multiple Myeloma: Current Status as Prologue to the Future

Abramson

2023

IJMS

View full text Add to dashboard Cite

The landscape of therapeutic measures to treat multiple myeloma has undergone a seismic shift since the dawn of the current century. This has been driven largely by the introduction of new classes of small molecules, such as proteasome blockers (e.g., bortezomib) and immunomodulators (e.g., lenalidomide), as well as by immunotherapeutic agents starting with the anti-CD38 monoclonal antibody daratumumab in 2015. Recently, other immunotherapies have been added to the armamentarium of drugs available to fight this malignancy. These include the bispecifics teclistamab, talquetamab, and elranatamab, and the chimeric antigen receptor (CAR) T-cell products idecabtagene vicleucel (ide-cel) and ciltacabtagene autoleucel (cilta-cel). While the accumulated benefits of these newer agents have resulted in a more than doubling of the disease’s five-year survival rate to nearly 60% and improved quality of life, the disease remains incurable, as patients become refractory to the drugs and experience relapse. This review covers the current scope of antimyeloma immunotherapeutic agents, both those in clinical use and in development. Included in the discussion are additional monoclonal antibodies (mAbs), antibody–drug conjugates (ADCs), bi- and multitargeted mAbs, and CAR T-cells and emerging natural killer (NK) cells, including products intended for “off-the-shelf” (allogeneic) applications. Emphasis is placed on the benefits of each along with the challenges that need to be surmounted if MM is to be cured.

show abstract

Section: Discussionmentioning

confidence: 99%

Immunotherapy of Multiple Myeloma: Current Status as Prologue to the Future

Abramson

2023

IJMS

View full text Add to dashboard Cite

show abstract

“…Simone Oerlemans, 1 Belle H. de Rooij, 1,2+ Christine Bennink, 3,4+ Lars Bullinger, 5 Annemiek Broijl, 4 Mattia D'Agostino, 6 Edward Laane, 7 Maria Teresa Lupo-Stanghellini, 8 Aurore Perrot, 9 Ruth Wester, 4 Viorica Cursaru, 10 Hans Scheurer, 11 Jan Vesseur, 11 Mehul Dalal, 12 Rohini Sen, 13 Tanja Stamm, 14 12 Takeda Development Center Americas Inc., Lexington, MA, USA; 13 Abbvie, Somerville, MA, USA; 14 Institute of…”

Section: Authorsmentioning

confidence: 99%

Update and European consensus on a patient-centered core outcome set for multiple myeloma in clinical practice and research

Oerlemans,

De Rooij,

Bennink

et al. 2024

haematol

View full text Add to dashboard Cite

show abstract

“… 2 Currently available therapeutic options for RRMM mostly maintain HRQoL but do not achieve clinically meaningful improvements. 13 Comparisons across trials, however, are limited by differences in reporting of clinically meaningful improvements, and differences in patient populations and trial design. In the phase III APOLLO study of pomalidomide plus dexamethasone with or without daratumumab, HRQoL measured using the EORTC QLQ-C30 and EORTC QLQ-MY20 questionnaires remained generally consistent with baseline in both arms, although between-group differences did not favor the pomalidomide-dexamethasone arm for most QoL scales.…”

mentioning

confidence: 99%